<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName A++V2.4.dtd?>
<?SourceDTD.Version 2.4?>
<?ConverterInfo.XSLTName springer2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">J Transl Med</journal-id>
    <journal-id journal-id-type="iso-abbrev">J Transl Med</journal-id>
    <journal-title-group>
      <journal-title>Journal of Translational Medicine</journal-title>
    </journal-title-group>
    <issn pub-type="epub">1479-5876</issn>
    <publisher>
      <publisher-name>BioMed Central</publisher-name>
      <publisher-loc>London</publisher-loc>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">8254928</article-id>
    <article-id pub-id-type="publisher-id">2942</article-id>
    <article-id pub-id-type="doi">10.1186/s12967-021-02942-y</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Research</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>An easy-to-operate web-based calculator for predicting the progression of chronic kidney disease</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" equal-contrib="yes">
        <name>
          <surname>Xu</surname>
          <given-names>Qian</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author" equal-contrib="yes">
        <name>
          <surname>Wang</surname>
          <given-names>Yunyun</given-names>
        </name>
        <xref ref-type="aff" rid="Aff2">2</xref>
      </contrib>
      <contrib contrib-type="author" equal-contrib="yes">
        <name>
          <surname>Fang</surname>
          <given-names>Yiqun</given-names>
        </name>
        <xref ref-type="aff" rid="Aff3">3</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Feng</surname>
          <given-names>Shanshan</given-names>
        </name>
        <xref ref-type="aff" rid="Aff4">4</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Chen</surname>
          <given-names>Cuiyun</given-names>
        </name>
        <xref ref-type="aff" rid="Aff4">4</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <name>
          <surname>Jiang</surname>
          <given-names>Yanxia</given-names>
        </name>
        <address>
          <email>jiangyanxiancu@outlook.com</email>
        </address>
        <xref ref-type="aff" rid="Aff4">4</xref>
      </contrib>
      <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.412604.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1758 4073</institution-id><institution>Health Management Center, </institution><institution>First Affiliated Hospital of Nanchang University, </institution></institution-wrap>Nanchang, 330006 Jiangxi China </aff>
      <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.412604.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1758 4073</institution-id><institution>Academic Affairs Office, </institution><institution>First Affiliated Hospital of Nanchang University, </institution></institution-wrap>Nanchang, 330006 Jiangxi China </aff>
      <aff id="Aff3"><label>3</label>Department of Endocrinology and Metabolism, Jingdezhen First People’s Hospital, Jingdezhen, 333000 Jiangxi China </aff>
      <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.412604.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1758 4073</institution-id><institution>Department of Endocrinology and Metabolism, </institution><institution>First Affiliated Hospital of Nanchang University, </institution></institution-wrap>17 Yongwai, Nanchang, 330006 Jiangxi People’s Republic of China </aff>
    </contrib-group>
    <pub-date pub-type="epub">
      <day>3</day>
      <month>7</month>
      <year>2021</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>3</day>
      <month>7</month>
      <year>2021</year>
    </pub-date>
    <pub-date pub-type="collection">
      <year>2021</year>
    </pub-date>
    <volume>19</volume>
    <elocation-id>288</elocation-id>
    <history>
      <date date-type="received">
        <day>25</day>
        <month>3</month>
        <year>2021</year>
      </date>
      <date date-type="accepted">
        <day>13</day>
        <month>6</month>
        <year>2021</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2021</copyright-statement>
      <license>
        <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p>
      </license>
    </permissions>
    <abstract id="Abs1">
      <sec>
        <title>Background</title>
        <p id="Par1">This study aimed to establish and validate an easy-to-operate novel scoring system based on simple and readily available clinical indices for predicting the progression of chronic kidney disease (CKD).</p>
      </sec>
      <sec>
        <title>Methods</title>
        <p id="Par2">We retrospectively evaluated 1045 eligible CKD patients from a publicly available database. Factors included in the model were determined by univariate and multiple Cox proportional hazard analyses based on the training set.</p>
      </sec>
      <sec>
        <title>Results</title>
        <p id="Par3">Independent prognostic factors including etiology, hemoglobin level, creatinine level, proteinuria, and urinary protein/creatinine ratio were determined and contained in the model. The model showed good calibration and discrimination. The area under the curve (AUC) values generated to predict 1-, 2-, and 3-year progression-free survival in the training set were 0.947, 0.931, and 0.939, respectively. In the validation set, the model still revealed excellent calibration and discrimination, and the AUC values generated to predict 1-, 2-, and 3-year progression-free survival were 0.948, 0.933, and 0.915, respectively. In addition, decision curve analysis demonstrated that the model was clinically beneficial. Moreover, to visualize the prediction results, we established a web-based calculator (<ext-link ext-link-type="uri" xlink:href="https://ncutool.shinyapps.io/CKDprogression/">https://ncutool.shinyapps.io/CKDprogression/</ext-link>).</p>
      </sec>
      <sec>
        <title>Conclusion</title>
        <p id="Par4">An easy-to-operate model based on five relevant factors was developed and validated as a conventional tool to assist doctors with clinical decision-making and personalized treatment.</p>
      </sec>
    </abstract>
    <kwd-group xml:lang="en">
      <title>Keywords</title>
      <kwd>Chronic kidney disease</kwd>
      <kwd>End-stage renal disease</kwd>
      <kwd>Area under the curve</kwd>
      <kwd>Prognostic factor</kwd>
      <kwd>Progression-free survival</kwd>
    </kwd-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id>
            <institution>National Natural Science Foundation of China</institution>
          </institution-wrap>
        </funding-source>
        <award-id>82060043</award-id>
        <principal-award-recipient>
          <name>
            <surname>Jiang</surname>
            <given-names>Yanxia</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
    </funding-group>
    <custom-meta-group>
      <custom-meta>
        <meta-name>issue-copyright-statement</meta-name>
        <meta-value>© The Author(s) 2021</meta-value>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="Sec1">
    <title>Introduction</title>
    <p id="Par15">Chronic kidney disease (CKD), a common kidney disease with a progressive decline in renal function, is increasingly recognized as a global public health problem [<xref ref-type="bibr" rid="CR1">1</xref>]. It causes more than half a million patients to develop end-stage renal disease (ESRD) every year, and over 700,000 deaths [<xref ref-type="bibr" rid="CR2">2</xref>]. CKD is multifactorial and is defined as glomerular filtration rate (GFR) &lt; 60 mL/min per 1.73 m<sup>2</sup> or abnormalities in kidney structure or function present for more than 3 months [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. Diabetic nephropathy is the leading cause of CKD, accounting for approximately 40% of patients with non-dialysis-dependent CKD and ESRD [<xref ref-type="bibr" rid="CR5">5</xref>]. Other pathological processes for CKD include chronic glomerulonephritis, ureteral obstruction, and renal fibrosis [<xref ref-type="bibr" rid="CR6">6</xref>–<xref ref-type="bibr" rid="CR8">8</xref>]. As effective therapeutic strategies for ESRD are currently limited, it is important to identify treatments to delay the progression of CKD to ESRD. Rapid CKD progression leads to irreversible pathological changes and may be associated with unfavorable outcomes. Once a patient has developed ESRD, renal replacement therapy is needed to maintain their daily activities. Therefore, there is an urgent need for reliable and accurate progression prediction models for CKD.</p>
    <p id="Par16">Many definitions of CKD progression have been used over the years, such as doubling of serum creatinine level, decrease in estimated GFR (eGFR) to &lt; 15 mL/min per 1.73 m<sup>2</sup>, and development of ESRD [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Currently, there are no clinically robust biomarkers to predict progressive CKD. Rather, clinicians rely on multiple longitudinal kidney measurements, such as the eGFR, proteinuria, and urinary protein/creatinine ratio (UPCR) to identify progression [<xref ref-type="bibr" rid="CR11">11</xref>]. The shortcomings of these traditional biomarkers are well recognized, and a single index has limited predictive capacity for progressive CKD [<xref ref-type="bibr" rid="CR12">12</xref>]. However, the use of complex and potentially expensive detection strategies may prevent at risk patients from benefiting from preventative interventions, especially in settings where renal replacement therapy is not readily available. The use of risk models is an attractive and likely cost-effective method for large-scale CKD risk stratification and would allow the identification of populations that would benefit the most from CKD detection. There have been several attempts to create a risk model for predicting the progression of CKD. However, the prediction accuracy of these models has not been tested through widespread application in clinical practice [<xref ref-type="bibr" rid="CR13">13</xref>–<xref ref-type="bibr" rid="CR16">16</xref>].</p>
    <p id="Par17">In the present study, we aimed to establish a model using Cox regression analysis based on commonly used and readily available clinical characteristics to predict disease progression in CKD patients. We performed univariate and multivariate analyses to screen for independent risk factors. The visualization model was constructed by nomogram and web-based calculator, and prediction performance was measured by discrimination, calibration, and clinical utility. This novel simple-to-use model might predict the prognosis of patients with CKD with high accuracy.</p>
  </sec>
  <sec id="Sec2">
    <title>Methods</title>
    <sec id="Sec3">
      <title>Ethics statement</title>
      <p id="Par18">The study was conducted in accordance with the ethical standards and the Declaration of Helsinki and according to national and international guidelines. It was approved by the authors' institutional review board (No. 883).</p>
    </sec>
    <sec id="Sec4">
      <title>Patients</title>
      <p id="Par19">This study used data from 1138 patients with CKD obtained via the Dryad Digital Repository (<ext-link ext-link-type="uri" xlink:href="http://www.datadryad.org/">http://www.datadryad.org/</ext-link>), shared by Limori et al. [<xref ref-type="bibr" rid="CR17">17</xref>]. According to Dryad's terms of service, researchers can use these data for secondary analysis without infringing on the author's rights. All eligible individuals who were not undergoing dialysis were diagnosed with stage G2–G5 CKD based on the Kidney Disease Improving Global Outcomes classification [<xref ref-type="bibr" rid="CR18">18</xref>]. All participants were at least 20 years of age and visited nephrology centers for the first time between October 2010 and December 2011. Patients with malignancy that was diagnosed or treated within the previous 2 years, transplant recipients, and those with active gastrointestinal bleeding at enrollment were excluded. All eligible patients were randomly stratified into two groups in a 2:1 ratio (training set and validation set, respectively).</p>
    </sec>
    <sec id="Sec5">
      <title>Data collection</title>
      <p id="Par20">We performed a secondary analysis based on data from the above database. Fifteen probable prediction variables were selected, including gender, age, etiology (diabetes, nephrosclerosis, glomerulonephritis, and others), hemoglobin level, serum albumin level, creatinine level, eGFR, proteinuria, urinary occult blood, UPCR, hypertension, history of cardiovascular disease, diabetes, use of RAAS inhibitor, use of calcium channel blocker, and use of diuretics. Moreover, the vital status and follow-up time of each CKD case were extracted.</p>
    </sec>
    <sec id="Sec6">
      <title>Predictor selection and development of the prediction model</title>
      <p id="Par21">Depending on the training set, Cox proportion hazard regression models were used to screen potential prognostic factors and estimate their weights [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. Univariable Cox regression analysis was performed to explore the potential predictors [<xref ref-type="bibr" rid="CR21">21</xref>]. The selected prognostic factors (p value below 0.05 in univariate analysis) were then included in a multivariate Cox regression analysis to obtain an integrated nomogram by a stepwise feature selection algorithm based on the AIC [<xref ref-type="bibr" rid="CR22">22</xref>]. Moreover, to facilitate clinical application, we established a visualization tool by a web-based calculator.</p>
    </sec>
    <sec id="Sec7">
      <title>Validation of the prediction model</title>
      <p id="Par22">The performance of our model to predict survival was quantified using AUC values from the ROC analysis and the C-index. The performance of the novel model was also evaluated by examining calibration in training and validation sets. In addition, DCA was carried out to assess the clinical utility of the model. These tests were all performed in both the training and validation sets.</p>
    </sec>
    <sec id="Sec8">
      <title>Statistical analysis</title>
      <p id="Par23">Continuous variables following a normal distribution are presented as mean ± standard deviation and categorical variables are presented as percentages. Differences between the training and validation sets were analyzed using chi-square tests for the categorical variables and t-tests for the continuous variables. A p value &lt; 0.05 was used as a cutoff for statistical significance. Statistical analysis was performed using SPSS software (version 24.0) and R software (version 3.6.2).</p>
    </sec>
  </sec>
  <sec id="Sec9">
    <title>Results</title>
    <sec id="Sec10">
      <title>Baseline characteristics</title>
      <p id="Par24">Figure <xref rid="Fig1" ref-type="fig">1</xref> shows a flow diagram of the selection process. After excluding 93 patients with missing data, a total of 1,045 patients was included in the analysis. Patients were randomly divided at a ratio of 6:3 into training (N = 696) and validation sets (N = 349). The demographics and clinical characteristics of the whole, training, and validation sets are presented in Table <xref rid="Tab1" ref-type="table">1</xref>. In the whole cohort, 69.9% of the participants were male, and the mean age was 67.31 ± 13.6 years. Most patients had positive proteinuria and history of hypertension. Across the entire study population, 260 patients had disease progression (CKD progression defined as &gt; 50% eGFR loss or initiation of dialysis).<fig id="Fig1"><label>Fig. 1</label><caption><p>Flow diagram that shows the development and validation of the prediction model</p></caption><graphic xlink:href="12967_2021_2942_Fig1_HTML" id="MO1"/></fig><table-wrap id="Tab1"><label>Table 1</label><caption><p>Baseline demographics and clinical characteristics of patients in training cohort and validation cohort</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Variables</th><th align="left">All patients<break/>(N = 1045)</th><th align="left">Training set<break/>(N = 696)</th><th align="left">Validation set<break/>(N = 349)</th><th align="left">P-value</th></tr></thead><tbody><tr><td align="left">Gender, n (%)</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">0.966</td></tr><tr><td align="left"> Male</td><td align="left">730 (69.9%)</td><td align="left">487 (70.0%)</td><td align="left">243 (69.6%)</td><td align="left"/></tr><tr><td align="left"> Female</td><td align="left">315 (30.1%)</td><td align="left">209 (30.0%)</td><td align="left">106 (30.4%)</td><td align="left"/></tr><tr><td align="left">Age, years</td><td align="left">67.31 ± 13.60</td><td align="left">66.70 ± 13.90</td><td align="left">68.54 ± 12.90</td><td align="left">0.039</td></tr><tr><td align="left">Etiology, n (%)</td><td align="left"/><td align="left"/><td align="left"/><td align="left">0.759</td></tr><tr><td align="left"> Diabetic</td><td align="left">271 (25.9%)</td><td align="left">177 (25.4%)</td><td align="left">94 (26.9%)</td><td align="left"/></tr><tr><td align="left"> Nephrosclerosis</td><td align="left">411 (39.3%)</td><td align="left">270 (38.8%)</td><td align="left">141 (40.4%)</td><td align="left"/></tr><tr><td align="left"> Glomerulonephritis</td><td align="left">197 (18.9%)</td><td align="left">137 (19.7%)</td><td align="left">60 (17.2%)</td><td align="left"/></tr><tr><td align="left"> Others</td><td align="left">166 (15.9%)</td><td align="left">112 (16.1%)</td><td align="left">54 (15.5%)</td><td align="left"/></tr><tr><td align="left">Hemoglobin, g/dL</td><td align="left">11.97 ± 2.28</td><td align="left">12.02 ± 2.29</td><td align="left">11.87 ± 2.26</td><td align="left">0.304</td></tr><tr><td align="left">Serum albumin, g/dL</td><td align="left">3.85 ± 0.63</td><td align="left">3.87 ± 0.63</td><td align="left">3.82 ± 0.64</td><td align="left">0.211</td></tr><tr><td align="left">Creatinine, g/dL</td><td align="left">2.26 ± 1.72</td><td align="left">2.25 ± 1.72</td><td align="left">2.28 ± 1.71</td><td align="left">0.825</td></tr><tr><td align="left">eGFR, mL/min/1.73 m<sup>2</sup></td><td align="left">32.95 ± 18.82</td><td align="left">33.15 ± 18.78</td><td align="left">32.56 ± 18.90</td><td align="left">0.632</td></tr><tr><td align="left">Proteinuria, n (%)</td><td align="left"/><td align="left"/><td align="left"/><td align="left">0.919</td></tr><tr><td align="left"> Negative</td><td align="left">381 (36.5%)</td><td align="left">255 (36.6%)</td><td align="left">126 (36.1%)</td><td align="left"/></tr><tr><td align="left"> Positive</td><td align="left">664 (63.5%)</td><td align="left">441 (63.4%)</td><td align="left">223 (63.9%)</td><td align="left"/></tr><tr><td align="left">Urinary occult blood, n (%)</td><td align="left"/><td align="left"/><td align="left"/><td align="left">0.361</td></tr><tr><td align="left"> Negative</td><td align="left">689 (65.9%)</td><td align="left">466 (67.0%)</td><td align="left">223 (63.9%)</td><td align="left"/></tr><tr><td align="left"> Positive</td><td align="left">356 (34.1%)</td><td align="left">230 (33.0%)</td><td align="left">126 (36.1%)</td><td align="left"/></tr><tr><td align="left">UPCR, g/gCr</td><td align="left">2.17 ± 3.24</td><td align="left">2.04 ± 2.98</td><td align="left">2.42 ± 3.69</td><td align="left">0.073</td></tr><tr><td align="left">Hypertension, n (%)</td><td align="left"/><td align="left"/><td align="left"/><td align="left">0.864</td></tr><tr><td align="left"> No</td><td align="left">101 (9.7%)</td><td align="left">66 (9.5%)</td><td align="left">35 (10.0%)</td><td align="left"/></tr><tr><td align="left"> Yes</td><td align="left">944 (90.3%)</td><td align="left">630 (90.5%)</td><td align="left">314 (90.0%)</td><td align="left"/></tr><tr><td align="left">History of CVD, n (%)</td><td align="left"/><td align="left"/><td align="left"/><td align="left">0.183</td></tr><tr><td align="left"> No</td><td align="left">765 (73.2%)</td><td align="left">519 (74.6%)</td><td align="left">246 (70.5%)</td><td align="left"/></tr><tr><td align="left"> Yes</td><td align="left">280 (26.8%)</td><td align="left">177 (25.4%)</td><td align="left">103 (29.5%)</td><td align="left"/></tr><tr><td align="left">Diabetes, n (%)</td><td align="left"/><td align="left"/><td align="left"/><td align="left">0.693</td></tr><tr><td align="left"> No</td><td align="left">651 (62.3%)</td><td align="left">437 (62.8%)</td><td align="left">214 (61.3%)</td><td align="left"/></tr><tr><td align="left"> Yes</td><td align="left">394 (37.7%)</td><td align="left">259 (37.2%)</td><td align="left">135 (38.7%)</td><td align="left"/></tr><tr><td align="left">Use of RAAS inhibitor, n (%)</td><td align="left"/><td align="left"/><td align="left"/><td align="left">0.047</td></tr><tr><td align="left"> No</td><td align="left">380 (36.4%)</td><td align="left">238 (34.2%)</td><td align="left">142 (40.7%)</td><td align="left"/></tr><tr><td align="left"> Yes</td><td align="left">665 (63.6%)</td><td align="left">458 (65.8%)</td><td align="left">207 (59.3%)</td><td align="left"/></tr><tr><td align="left">Use of calcium channel blocker, n (%)</td><td align="left"/><td align="left"/><td align="left"/><td align="left">0.616</td></tr><tr><td align="left"> No</td><td align="left">547 (52.3%)</td><td align="left">360 (51.7%)</td><td align="left">187 (53.6%)</td><td align="left"/></tr><tr><td align="left"> Yes</td><td align="left">498 (47.7%)</td><td align="left">336 (48.3%)</td><td align="left">162 (46.4%)</td><td align="left"/></tr><tr><td align="left">Use of diuretics, n (%)</td><td align="left"/><td align="left"/><td align="left"/><td align="left">0.154</td></tr><tr><td align="left"> No</td><td align="left">694 (66.4%)</td><td align="left">473 (68.0%)</td><td align="left">221 (63.3%)</td><td align="left"/></tr><tr><td align="left"> Yes</td><td align="left">351 (33.6%)</td><td align="left">223 (32.0%)</td><td align="left">128 (36.7%)</td><td align="left"/></tr><tr><td align="left">Vital status, n (%)</td><td align="left"/><td align="left"/><td align="left"/><td align="left">0.773</td></tr><tr><td align="left"> Alive</td><td align="left">972 (93.0%)</td><td align="left">649 (93.2%)</td><td align="left">323 (92.6%)</td><td align="left"/></tr><tr><td align="left"> Deceased</td><td align="left">73(7.0%)</td><td align="left">47(6.8%)</td><td align="left">26 (7.4%)</td><td align="left"/></tr><tr><td align="left">CKD progression, n (%)</td><td align="left"/><td align="left"/><td align="left"/><td align="left">0.479</td></tr><tr><td align="left"> No</td><td align="left">785 (75.1%)</td><td align="left">528 (75.9%)</td><td align="left">257 (73.6%)</td><td align="left"/></tr><tr><td align="left"> Yes</td><td align="left">260 (24.9%)</td><td align="left">168 (24.1%)</td><td align="left">92 (26.4%)</td><td align="left"/></tr></tbody></table></table-wrap></p>
    </sec>
    <sec id="Sec11">
      <title>Prognostic factors of CKD</title>
      <p id="Par25">Univariate Cox regression analysis showed that age, etiology, hemoglobin level, serum albumin level, creatinine level, eGFR, proteinuria, urinary occult blood, UPCR, hypertension, diabetes, use of renin–angiotensin–aldosterone-system (RAAS) inhibitor, use of calcium channel blocker, and use of diuretics were correlated with CKD progression. Multivariate Cox regression analysis identified etiology, hemoglobin level, creatinine level, proteinuria, and UPCR as independent prognostic factors of CKD patients (Table <xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Univariate and multivariable Cox hazards analysis of the training cohort</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Variables</th><th align="left">Univariate</th><th align="left" rowspan="2"><italic>P</italic>-value</th><th align="left">Multivariate</th><th align="left" rowspan="2"><italic>P</italic>-value</th></tr><tr><th align="left">HR (95% CI)</th><th align="left">HR (95% CI)</th></tr></thead><tbody><tr><td align="left">Gender</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left"> Male</td><td align="left">Ref.</td><td align="left">–</td><td align="left">Ref.</td><td align="left">–</td></tr><tr><td align="left"> Female</td><td align="left">1.018 (0.734–1.412)</td><td align="left">0.914</td><td align="left"/><td align="left">–</td></tr><tr><td align="left">Age</td><td align="left">0.989 (0.979–0.999)</td><td align="left"><bold>0.028</bold></td><td align="left">0.998 (0.985–1.011)</td><td align="left">0.720</td></tr><tr><td align="left">Etiology</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Diabetic</td><td align="left">Ref.</td><td align="left"/><td align="left">Ref.</td><td align="left">–</td></tr><tr><td align="left">Nephrosclerosis</td><td align="left">0.147 (0.098–0.220)</td><td align="left"><bold>0.000</bold></td><td align="left">0.540 (0.297–0.979)</td><td align="left"><bold>0.042</bold></td></tr><tr><td align="left">Glomerulonephritis</td><td align="left">0.230 (0.148–0.359)</td><td align="left"><bold>0.000</bold></td><td align="left">0.437 (0.228–0.836)</td><td align="left"><bold>0.012</bold></td></tr><tr><td align="left">Others</td><td align="left">0.170 (0.097–0.299)</td><td align="left"><bold>0.000</bold></td><td align="left">0.269 (0.118–0.618)</td><td align="left"><bold>0.002</bold></td></tr><tr><td align="left">Hemoglobin</td><td align="left">0.701 (0.655–0.751)</td><td align="left"><bold>0.000</bold></td><td align="left">0.821 (0.749–0.900)</td><td align="left"><bold>0.000</bold></td></tr><tr><td align="left">Serum albumin</td><td align="left">0.267 (0.216–0.330)</td><td align="left"><bold>0.000</bold></td><td align="left">0.869 (0.624–1.212)</td><td align="left">0.409</td></tr><tr><td align="left">Creatinine</td><td align="left">1.429 (1.370–1.490)</td><td align="left"><bold>0.000</bold></td><td align="left">1.314 (1.221–1.413)</td><td align="left"><bold>0.000</bold></td></tr><tr><td align="left">Proteinuria</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left"> Negative</td><td align="left">Ref.</td><td align="left"/><td align="left">Ref.</td><td align="left"/></tr><tr><td align="left"> Positive</td><td align="left">28.395 (10.53–76.571)</td><td align="left"><bold>0.000</bold></td><td align="left">7.214 (2.547–20.436)</td><td align="left"><bold>0.000</bold></td></tr><tr><td align="left">Urinary occult blood</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left"> Negative</td><td align="left">Ref.</td><td align="left"/><td align="left">Ref.</td><td align="left"/></tr><tr><td align="left"> Positive</td><td align="left">2.156 (1.592–2.919)</td><td align="left"><bold>0.000</bold></td><td align="left">1.096 (0.779–1.543)</td><td align="left">0.597</td></tr><tr><td align="left">UPCR</td><td align="left">1.305 (1.264–1.348)</td><td align="left"><bold>0.000</bold></td><td align="left">1.192 (1.126–1.261)</td><td align="left"><bold>0.000</bold></td></tr><tr><td align="left">Hypertension</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left"> No</td><td align="left">Ref.</td><td align="left"/><td align="left">Ref.</td><td align="left"/></tr><tr><td align="left"> Yes</td><td align="left">5.976 (1.908–18.719)</td><td align="left"><bold>0.002</bold></td><td align="left">0.930 (0.271–3.197)</td><td align="left">0.909</td></tr><tr><td align="left">History of CVD</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left"> No</td><td align="left">Ref.</td><td align="left">–</td><td align="left">Ref.</td><td align="left">–</td></tr><tr><td align="left"> Yes</td><td align="left">1.366 (0.977–1.910)</td><td align="left">0.068</td><td align="left"/><td align="left">–</td></tr><tr><td align="left">Diabetes</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left"> No</td><td align="left">Ref.</td><td align="left">–</td><td align="left">Ref.</td><td align="left">–</td></tr><tr><td align="left"> Yes</td><td align="left">3.005 (2.205–4.096)</td><td align="left"><bold>0.000</bold></td><td align="left">0.898 (0.527–1.528)</td><td align="left">0.690</td></tr><tr><td align="left">Use of RAAS inhibitor</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left"> No</td><td align="left">Ref.</td><td align="left"><bold>–</bold></td><td align="left">Ref.</td><td align="left">–</td></tr><tr><td align="left"> Yes</td><td align="left">1.808 (1.259–2.595)</td><td align="left"><bold>0.001</bold></td><td align="left">0.928 (0.627–1.374)</td><td align="left">0.710</td></tr><tr><td align="left">Use of calcium channel blocker</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left"> No</td><td align="left">Ref.</td><td align="left"><bold>−</bold></td><td align="left">Ref.</td><td align="left">–</td></tr><tr><td align="left"> Yes</td><td align="left">2.024 (1.474–2.778)</td><td align="left"><bold>0.000</bold></td><td align="left">1.298 (0.925–1.821)</td><td align="left">0.132</td></tr><tr><td align="left">Use of diuretics</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left"> No</td><td align="left">Ref.</td><td align="left"><bold>–</bold></td><td align="left">Ref.</td><td align="left">–</td></tr><tr><td align="left"> Yes</td><td align="left">2.833 (2.092–3.836)</td><td align="left"><bold>0.000</bold></td><td align="left">1.04 (0.741–1.461)</td><td align="left">0.819</td></tr></tbody></table><table-wrap-foot><p><italic>P</italic> &lt; 0.05 is shown in bold</p></table-wrap-foot></table-wrap></p>
    </sec>
    <sec id="Sec12">
      <title>Development of an individualized prediction model</title>
      <p id="Par26">Based on Akaike information criterion (AIC) results, five factors (etiology, hemoglobin, creatinine, proteinuria, and UPCR) were selected to establish the predictive nomogram, which is an intuitive visualization of the model (Fig. <xref rid="Fig2" ref-type="fig">2</xref>A). According to the constructed model, the risk score of each sample was calculated according to the model coefficients combined with the corresponding value of the five chosen factors. CKD patients were divided into high- (N = 348) and low-risk (N = 348) groups based on their median risk score. Risk score distribution is shown in Fig. <xref rid="Fig2" ref-type="fig">2</xref>B. The Kaplan–Meier survival curve of low- and high-risk groups in the training set is shown in Fig. <xref rid="Fig2" ref-type="fig">2</xref>C (p &lt; 0.001). The CKD progression status and follow-up time of each individual is shown in Fig. <xref rid="Fig2" ref-type="fig">2</xref>D.<fig id="Fig2"><label>Fig. 2</label><caption><p>The model to predict the probability of progression in chronic kidney disease (CKD) patients from the training cohort. <bold>A</bold> The nomogram based on the five variables identified by the Cox hazards analysis. <bold>B</bold> Distribution of the risk scores calculated by the nomogram scoring system. <bold>C</bold> Progression-free survival curves stratified by the low- and high-score groups. <bold>D</bold> Patient distribution in the low- and high-score groups based on progression status</p></caption><graphic xlink:href="12967_2021_2942_Fig2_HTML" id="MO2"/></fig></p>
    </sec>
    <sec id="Sec13">
      <title>Establishment of a web-based calculator</title>
      <p id="Par27">For convenient clinical use and visualization of the prognostic model, we developed an easy-to-operate web-based model (<ext-link ext-link-type="uri" xlink:href="https://ncutool.shinyapps.io/CKDprogression/">https://ncutool.shinyapps.io/CKDprogression/</ext-link>) to predict the progression of CKD based on the established nomogram (Fig. <xref rid="Fig3" ref-type="fig">3</xref>). Estimated disease progression probabilities can be obtained by drawing a perpendicular line from the total point axis to the outcome axis.<fig id="Fig3"><label>Fig. 3</label><caption><p>Establishing an easy-to-operate web-based calculator for predicting the progression of chronic kidney disease (<ext-link ext-link-type="uri" xlink:href="https://ncutool.shinyapps.io/CKDprogression/">https://ncutool.shinyapps.io/CKDprogression/</ext-link>). <bold>A</bold> Web progression-free survival rate calculator. <bold>B</bold> 95% confidence interval of the web progression-free survival rate</p></caption><graphic xlink:href="12967_2021_2942_Fig3_HTML" id="MO3"/></fig></p>
    </sec>
    <sec id="Sec14">
      <title>Model performance in the training set</title>
      <p id="Par28">In the training set, the model was evaluated using time-dependent receiver operating characteristic (ROC) curve analysis over 1-, 2-, and 3-years, along with the concordance index (C-index). The area under the ROC curve (AUC) values for the 1-, 2-, and 3-year survival probabilities were 0.947, 0.931, and 0.939, respectively (Fig. <xref rid="Fig4" ref-type="fig">4</xref>A). The C-index for the prediction of progression-free survival was 0.912. The calibration curves of the model showed good probability consistencies between the predicted and observed values (Fig. <xref rid="Fig4" ref-type="fig">4</xref>B). These results might confirm that our model was reliable in predicting the prognosis of CKD. Furthermore, a decision curve analysis (DCA) confirmed our expectations, as the analysis revealed that the net benefit in 1-, 2- and 3-year predictions was the highest in the combined nomogram model compared to the single variable (Fig. <xref rid="Fig4" ref-type="fig">4</xref>C). Hence, we chose the combined model for clinical use.<fig id="Fig4"><label>Fig. 4</label><caption><p>Model discrimination and performance in the training set. <bold>A</bold> Receiver operating characteristic curves for model-based progression-free survival prediction. <bold>B</bold> Calibration plot examining estimation accuracy. <bold>C</bold> Decision curve analysis assessing clinical utility</p></caption><graphic xlink:href="12967_2021_2942_Fig4_HTML" id="MO4"/></fig></p>
    </sec>
    <sec id="Sec15">
      <title>Model performance in the validation set</title>
      <p id="Par29">In the validation set, CKD patients were divided into high- (N = 174) and low-risk (N = 175) cohorts based on their median risk score. The risk score distribution is shown in Fig. <xref rid="Fig5" ref-type="fig">5</xref>A. The CKD progression status and follow-up time of all individuals are shown in Fig. <xref rid="Fig5" ref-type="fig">5</xref>B. The Kaplan–Meier survival curve of the low- and high-risk groups is shown in Fig. <xref rid="Fig5" ref-type="fig">5</xref>C (p &lt; 0.001). The time-dependent ROC curve analysis validated prediction accuracy of this model over other features (Fig. <xref rid="Fig5" ref-type="fig">5</xref>C).<fig id="Fig5"><label>Fig. 5</label><caption><p>Validation of the nomogram in the validation set. <bold>A</bold> Distribution of the risk scores calculated by the nomogram scoring system. <bold>B</bold> Patient distribution in the low- and high-score groups based on progression status. <bold>C</bold> Progression-free survival curves stratified by the low- and high-score groups. <bold>D</bold> Time-dependent ROC curves for nomogram vs. other single parameters included in the model</p></caption><graphic xlink:href="12967_2021_2942_Fig5_HTML" id="MO5"/></fig></p>
      <p id="Par30">In addition, we performed calibration plot analysis in the validation set. The calibration curves of the model showed good probability consistencies between the predicted and observed values (Fig. <xref rid="Fig6" ref-type="fig">6</xref>A). DCA analysis revealed that the net benefit in the 1-, 2- and 3-year predictions was the highest in the combined nomogram model compared to the single variable (Fig. <xref rid="Fig6" ref-type="fig">6</xref>B).<fig id="Fig6"><label>Fig. 6</label><caption><p>Assessment of the model in the validation set. <bold>A</bold> Calibration plot examining estimation accuracy. <bold>B</bold> Decision curve analysis assessing clinical utility</p></caption><graphic xlink:href="12967_2021_2942_Fig6_HTML" id="MO6"/></fig></p>
    </sec>
  </sec>
  <sec id="Sec16">
    <title>Discussion</title>
    <p id="Par31">Predicting the CKD outcome in individual patients is beneficial for identifying those who need an aggressive therapeutic regimen. This study showed that etiology, together with proteinuria, serum creatinine, and UPCR, was a better predictor of the risk of progression in patients with CKD when compared to a single indicator. Furthermore, a novel nomogram and corresponding web-based calculator were built as a reference for clinicians to help with clinical decision-making. The risk score identified the highest risk patients accurately, and therefore can identify patients who may benefit most from management by nephrologists without referring the entire population with CKD to them.</p>
    <p id="Par32">The etiology of CKD is multifactorial and diverse. The main causes included diabetes, nephrosclerosis, and glomerulonephritis. In the present study, we found that the highest risk of progression is diabetic kidney disease (DKD). Type 2 diabetes is the most common cause of severe kidney disease worldwide, and DKD is associated with premature death [<xref ref-type="bibr" rid="CR23">23</xref>]. Although, the fundamental mechanism responsible for the development of DKD to ESRD is poorly understood [<xref ref-type="bibr" rid="CR24">24</xref>], it is now believed that vessel disease and inflammation are the main pathological mechanisms of CKD [<xref ref-type="bibr" rid="CR25">25</xref>]. Approximately 40% of diabetic patients develop DKD, and the resultant kidney damage often leads to kidney failure, ultimately requiring dialysis or kidney transplant [<xref ref-type="bibr" rid="CR26">26</xref>]. Our results suggest that measures should be taken to delay the progression of CKD, especially in cases of DKD.</p>
    <p id="Par33">Proteinuria generally precedes the loss of renal function in kidney disease [<xref ref-type="bibr" rid="CR27">27</xref>]. For instance, a population-based cohort study in China found that elevated albuminuria was a key predictor of progression to CKD or ESRD and indicated a higher risk of cardiovascular disease and mortality [<xref ref-type="bibr" rid="CR28">28</xref>]. However, an increasing number of studies have cast doubt on this classic paradigm. In several recent studies, eGFR reduced to 20–39% resulted in normal albuminuria levels [<xref ref-type="bibr" rid="CR29">29</xref>–<xref ref-type="bibr" rid="CR31">31</xref>]. In some clinical trials, improvement in proteinuria did not translate to an increased GFR or a reduction in end points such as the need for dialysis or death [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. The critical role of proteinuria as a single predictor of CKD prognosis requires further study. In the current study, incorporation of several factors including proteinuria might increase model accuracy.</p>
    <p id="Par34">Anemia is a common feature at any stage of CKD, especially in patients with advanced stages of CKD. Anemia in CKD is mainly attributable to the relative decrease in erythropoietin production by the kidneys, absolute or functional iron deficiency, and shortened red blood cell survival. The severity of anemia increases with CKD progression and affects nearly all patients with ESRD [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. The development of erythropoietic stimulatory agents, such as recombinant human erythropoietin and darbepoetin alpha, has resulted in substantial health benefits for patients with end-stage renal failure, including improved quality of life, reduced blood transfusion requirements, decreased left ventricular mass, diminished sleep disturbance, and enhanced exercise capacity [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. It is generally believed that low levels of hemoglobin are associated with worse outcomes in patients with CKD [<xref ref-type="bibr" rid="CR38">38</xref>]. These results are in agreement with the findings of our model.</p>
    <p id="Par35">Previous studies have tried to establish models for progression of CKD to kidney failure [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]. Although the estimations produced by previous models were moderately accurate, the results were somewhat complex because many predictors were involved, each with precise classification levels. We identified five easily accessible and simple demographic and clinical characteristics to include in our novel model, which demonstrated that these traditional factors are important in patients with CKD. Our model showed good calibration and discrimination, and the AUC values generated to predict 1-, 2-, and 3-year progression-free survival in the training set were 0.947, 0.931, and 0.939, respectively. In the validation set, the model revealed excellent calibration and discrimination, and the AUC values generated to predict 1-, 2-, and 3-year progression-free survival were 0.948, 0.933, and 0.915, respectively. These results showed that our model can perfectly predict patient survival in CKD. Moreover, we developed an easy-to-operate calculator that allows the public to freely predict local cases and diagnose the adaptability of the model.</p>
    <p id="Par36">Admittedly, there are some shortcomings in our research. First, the model was developed based on the five variables. However, these factors were unstable throughout the follow-up period, which might have partly influenced the precision of the model. Second, although the performance of the model was good in both the training and validation sets, multicenter clinical application is needed to evaluate the external utility of this model. Third, as the main outcome measure was the progression status of CKD, other outcomes such as survival time should be evaluated in future studies.</p>
    <p id="Par37">In conclusion, we constructed and validated a model incorporating five clinical characteristics (etiology, proteinuria, hemoglobin, creatinine, and UPCR) to predict disease progression in CKD patients. This model could serve as a reliable tool for determining CKD treatment strategies and potential outcomes.</p>
  </sec>
</body>
<back>
  <glossary>
    <title>Abbreviations</title>
    <def-list>
      <def-item>
        <term>CKD</term>
        <def>
          <p id="Par5">Chronic kidney disease</p>
        </def>
      </def-item>
      <def-item>
        <term>AUC</term>
        <def>
          <p id="Par6">Area under the curve</p>
        </def>
      </def-item>
      <def-item>
        <term>ESRD</term>
        <def>
          <p id="Par7">End-stage renal disease</p>
        </def>
      </def-item>
      <def-item>
        <term>GFR</term>
        <def>
          <p id="Par8">Glomerular filtration rate</p>
        </def>
      </def-item>
      <def-item>
        <term>eGFR</term>
        <def>
          <p id="Par9">Estimated glomerular filtration rate</p>
        </def>
      </def-item>
      <def-item>
        <term>UPCR</term>
        <def>
          <p id="Par10">Urinary protein/creatinine ratio</p>
        </def>
      </def-item>
      <def-item>
        <term>RAAS</term>
        <def>
          <p id="Par11">Renin–angiotensin–aldosterone-system</p>
        </def>
      </def-item>
      <def-item>
        <term>AIC</term>
        <def>
          <p id="Par12">Akaike information criterion</p>
        </def>
      </def-item>
      <def-item>
        <term>ROC</term>
        <def>
          <p id="Par13">Receiver operating characteristic</p>
        </def>
      </def-item>
      <def-item>
        <term>DCA</term>
        <def>
          <p id="Par14">Decision curve analysis; C-index, concordance index</p>
        </def>
      </def-item>
    </def-list>
  </glossary>
  <fn-group>
    <fn>
      <p>
        <bold>Publisher's Note</bold>
      </p>
      <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
    </fn>
    <fn>
      <p>Qian Xu, Yunyun Wang and Yiqun Fang contributed equally to this work</p>
    </fn>
  </fn-group>
  <ack>
    <title>Acknowledgements</title>
    <p>We would like to thank the investigators of Tokyo Medical and Dental University Hospital and its affiliated hospitals for sharing their data.</p>
  </ack>
  <notes notes-type="author-contribution">
    <title>Authors' contributions</title>
    <p>QX, YW and YF collected and analyzed the data; FF and CC analyzed and interpreted the data; YJ conceived the study. All authors read and approved the final manuscript.</p>
  </notes>
  <notes notes-type="funding-information">
    <title>Funding</title>
    <p>This work was supported by the National Natural Science Foundation of China (No. 82060043).</p>
  </notes>
  <notes notes-type="data-availability">
    <title>Availability of data and materials</title>
    <p>All the data were obtained from the Dryad Digital Repository (<ext-link ext-link-type="uri" xlink:href="http://www.datadryad.org/">http://www.datadryad.org/</ext-link>).</p>
  </notes>
  <notes>
    <title>Declarations</title>
    <notes id="FPar1">
      <title>Ethics approval and consent to participate</title>
      <p id="Par38">The present study was approved by the Ethics Committee and Institutional Review Board of affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University.</p>
    </notes>
    <notes id="FPar2">
      <title>Consent for publication</title>
      <p id="Par39">Not applicable.</p>
    </notes>
    <notes id="FPar3" notes-type="COI-statement">
      <title>Competing interests</title>
      <p id="Par40">The authors declare that they have no competing interests.</p>
    </notes>
  </notes>
  <ref-list id="Bib1">
    <title>References</title>
    <ref id="CR1">
      <label>1.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bikbov</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Purcell</surname>
            <given-names>CA</given-names>
          </name>
          <name>
            <surname>Levey</surname>
            <given-names>AS</given-names>
          </name>
          <name>
            <surname>Smith</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Abdoli</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Abebe</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Adebayo</surname>
            <given-names>OM</given-names>
          </name>
          <name>
            <surname>Afarideh</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Agarwal</surname>
            <given-names>SK</given-names>
          </name>
          <name>
            <surname>Agudelo-Botero</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Ahmadian</surname>
            <given-names>E</given-names>
          </name>
        </person-group>
        <article-title>Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017</article-title>
        <source>Lancet</source>
        <year>2020</year>
        <volume>395</volume>
        <fpage>709</fpage>
        <lpage>733</lpage>
        <pub-id pub-id-type="doi">10.1016/S0140-6736(20)30045-3</pub-id>
        <pub-id pub-id-type="pmid">32061315</pub-id>
      </element-citation>
    </ref>
    <ref id="CR2">
      <label>2.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lozano</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Naghavi</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Foreman</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Lim</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Shibuya</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Aboyans</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Abraham</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Adair</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Aggarwal</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Ahn</surname>
            <given-names>SY</given-names>
          </name>
          <name>
            <surname>Alvarado</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Anderson</surname>
            <given-names>HR</given-names>
          </name>
          <name>
            <surname>Anderson</surname>
            <given-names>LM</given-names>
          </name>
          <name>
            <surname>Andrews</surname>
            <given-names>KG</given-names>
          </name>
          <name>
            <surname>Atkinson</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Baddour</surname>
            <given-names>LM</given-names>
          </name>
          <name>
            <surname>Barker-Collo</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Bartels</surname>
            <given-names>DH</given-names>
          </name>
          <name>
            <surname>Bell</surname>
            <given-names>ML</given-names>
          </name>
          <name>
            <surname>Benjamin</surname>
            <given-names>EJ</given-names>
          </name>
          <name>
            <surname>Bennett</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Bhalla</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Bikbov</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Bin Abdulhak</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Birbeck</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Blyth</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Bolliger</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Boufous</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Bucello</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Burch</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Burney</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Carapetis</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Chou</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Chugh</surname>
            <given-names>SS</given-names>
          </name>
          <name>
            <surname>Coffeng</surname>
            <given-names>LE</given-names>
          </name>
          <name>
            <surname>Colan</surname>
            <given-names>SD</given-names>
          </name>
          <name>
            <surname>Colquhoun</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Colson</surname>
            <given-names>KE</given-names>
          </name>
          <name>
            <surname>Condon</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Connor</surname>
            <given-names>MD</given-names>
          </name>
          <name>
            <surname>Cooper</surname>
            <given-names>LT</given-names>
          </name>
          <name>
            <surname>Corriere</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Cortinovis</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>de Vaccaro</surname>
            <given-names>KC</given-names>
          </name>
          <name>
            <surname>Couser</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Cowie</surname>
            <given-names>BC</given-names>
          </name>
          <name>
            <surname>Criqui</surname>
            <given-names>MH</given-names>
          </name>
          <name>
            <surname>Cross</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Dabhadkar</surname>
            <given-names>KC</given-names>
          </name>
          <name>
            <surname>Dahodwala</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>De Leo</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Degenhardt</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Delossantos</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Denenberg</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Des Jarlais</surname>
            <given-names>DC</given-names>
          </name>
          <name>
            <surname>Dharmaratne</surname>
            <given-names>SD</given-names>
          </name>
          <name>
            <surname>Dorsey</surname>
            <given-names>ER</given-names>
          </name>
          <name>
            <surname>Driscoll</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Duber</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Ebel</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Erwin</surname>
            <given-names>PJ</given-names>
          </name>
          <name>
            <surname>Espindola</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Ezzati</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Feigin</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Flaxman</surname>
            <given-names>AD</given-names>
          </name>
          <name>
            <surname>Forouzanfar</surname>
            <given-names>MH</given-names>
          </name>
          <name>
            <surname>Fowkes</surname>
            <given-names>FG</given-names>
          </name>
          <name>
            <surname>Franklin</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Fransen</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Freeman</surname>
            <given-names>MK</given-names>
          </name>
          <name>
            <surname>Gabriel</surname>
            <given-names>SE</given-names>
          </name>
          <name>
            <surname>Gakidou</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Gaspari</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Gillum</surname>
            <given-names>RF</given-names>
          </name>
          <name>
            <surname>Gonzalez-Medina</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Halasa</surname>
            <given-names>YA</given-names>
          </name>
          <name>
            <surname>Haring</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Harrison</surname>
            <given-names>JE</given-names>
          </name>
          <name>
            <surname>Havmoeller</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Hay</surname>
            <given-names>RJ</given-names>
          </name>
          <name>
            <surname>Hoen</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Hotez</surname>
            <given-names>PJ</given-names>
          </name>
          <name>
            <surname>Hoy</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Jacobsen</surname>
            <given-names>KH</given-names>
          </name>
          <name>
            <surname>James</surname>
            <given-names>SL</given-names>
          </name>
          <name>
            <surname>Jasrasaria</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Jayaraman</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Johns</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Karthikeyan</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Kassebaum</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Keren</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Khoo</surname>
            <given-names>JP</given-names>
          </name>
          <name>
            <surname>Knowlton</surname>
            <given-names>LM</given-names>
          </name>
          <name>
            <surname>Kobusingye</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Koranteng</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Krishnamurthi</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Lipnick</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Lipshultz</surname>
            <given-names>SE</given-names>
          </name>
          <name>
            <surname>Ohno</surname>
            <given-names>SL</given-names>
          </name>
          <name>
            <surname>Mabweijano</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>MacIntyre</surname>
            <given-names>MF</given-names>
          </name>
          <name>
            <surname>Mallinger</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>March</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Marks</surname>
            <given-names>GB</given-names>
          </name>
          <name>
            <surname>Marks</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Matsumori</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Matzopoulos</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Mayosi</surname>
            <given-names>BM</given-names>
          </name>
          <name>
            <surname>McAnulty</surname>
            <given-names>JH</given-names>
          </name>
          <name>
            <surname>McDermott</surname>
            <given-names>MM</given-names>
          </name>
          <name>
            <surname>McGrath</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Mensah</surname>
            <given-names>GA</given-names>
          </name>
          <name>
            <surname>Merriman</surname>
            <given-names>TR</given-names>
          </name>
          <name>
            <surname>Michaud</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Miller</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Miller</surname>
            <given-names>TR</given-names>
          </name>
          <name>
            <surname>Mock</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Mocumbi</surname>
            <given-names>AO</given-names>
          </name>
          <name>
            <surname>Mokdad</surname>
            <given-names>AA</given-names>
          </name>
          <name>
            <surname>Moran</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Mulholland</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Nair</surname>
            <given-names>MN</given-names>
          </name>
          <name>
            <surname>Naldi</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Narayan</surname>
            <given-names>KM</given-names>
          </name>
          <name>
            <surname>Nasseri</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Norman</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>O'Donnell</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Omer</surname>
            <given-names>SB</given-names>
          </name>
          <name>
            <surname>Ortblad</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Osborne</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Ozgediz</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Pahari</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Pandian</surname>
            <given-names>JD</given-names>
          </name>
          <name>
            <surname>Rivero</surname>
            <given-names>AP</given-names>
          </name>
          <name>
            <surname>Padilla</surname>
            <given-names>RP</given-names>
          </name>
          <name>
            <surname>Perez-Ruiz</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Perico</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Phillips</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Pierce</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Pope</surname>
            <given-names>CA</given-names>
            <suffix>3rd</suffix>
          </name>
          <name>
            <surname>Porrini</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Pourmalek</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Raju</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Ranganathan</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Rehm</surname>
            <given-names>JT</given-names>
          </name>
          <name>
            <surname>Rein</surname>
            <given-names>DB</given-names>
          </name>
          <name>
            <surname>Remuzzi</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Rivara</surname>
            <given-names>FP</given-names>
          </name>
          <name>
            <surname>Roberts</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>De León</surname>
            <given-names>FR</given-names>
          </name>
          <name>
            <surname>Rosenfeld</surname>
            <given-names>LC</given-names>
          </name>
          <name>
            <surname>Rushton</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Sacco</surname>
            <given-names>RL</given-names>
          </name>
          <name>
            <surname>Salomon</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Sampson</surname>
            <given-names>U</given-names>
          </name>
          <name>
            <surname>Sanman</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Schwebel</surname>
            <given-names>DC</given-names>
          </name>
          <name>
            <surname>Segui-Gomez</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Shepard</surname>
            <given-names>DS</given-names>
          </name>
          <name>
            <surname>Singh</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Singleton</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Sliwa</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Smith</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Steer</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Taylor</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Thomas</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Tleyjeh</surname>
            <given-names>IM</given-names>
          </name>
          <name>
            <surname>Towbin</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Truelsen</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Undurraga</surname>
            <given-names>EA</given-names>
          </name>
          <name>
            <surname>Venketasubramanian</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Vijayakumar</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Vos</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Wagner</surname>
            <given-names>GR</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Watt</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Weinstock</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Weintraub</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Wilkinson</surname>
            <given-names>JD</given-names>
          </name>
          <name>
            <surname>Woolf</surname>
            <given-names>AD</given-names>
          </name>
          <name>
            <surname>Wulf</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Yeh</surname>
            <given-names>PH</given-names>
          </name>
          <name>
            <surname>Yip</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Zabetian</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Zheng</surname>
            <given-names>ZJ</given-names>
          </name>
          <name>
            <surname>Lopez</surname>
            <given-names>AD</given-names>
          </name>
          <name>
            <surname>Murray</surname>
            <given-names>CJ</given-names>
          </name>
          <name>
            <surname>AlMazroa</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Memish</surname>
            <given-names>ZA</given-names>
          </name>
        </person-group>
        <article-title>Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010</article-title>
        <source>Lancet</source>
        <year>2012</year>
        <volume>380</volume>
        <fpage>2095</fpage>
        <lpage>2128</lpage>
        <pub-id pub-id-type="doi">10.1016/S0140-6736(12)61728-0</pub-id>
        <pub-id pub-id-type="pmid">23245604</pub-id>
      </element-citation>
    </ref>
    <ref id="CR3">
      <label>3.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Stevens</surname>
            <given-names>PE</given-names>
          </name>
          <name>
            <surname>Levin</surname>
            <given-names>A</given-names>
          </name>
        </person-group>
        <article-title>Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline</article-title>
        <source>Ann Intern Med</source>
        <year>2013</year>
        <volume>158</volume>
        <fpage>825</fpage>
        <lpage>830</lpage>
        <pub-id pub-id-type="doi">10.7326/0003-4819-158-11-201306040-00007</pub-id>
        <pub-id pub-id-type="pmid">23732715</pub-id>
      </element-citation>
    </ref>
    <ref id="CR4">
      <label>4.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Petreski</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Piko</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Ekart</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Hojs</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Bevc</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <article-title>Review on inflammation markers in chronic kidney disease</article-title>
        <source>Biomedicines</source>
        <year>2021</year>
        <volume>9</volume>
        <fpage>182</fpage>
        <pub-id pub-id-type="doi">10.3390/biomedicines9020182</pub-id>
        <pub-id pub-id-type="pmid">33670423</pub-id>
      </element-citation>
    </ref>
    <ref id="CR5">
      <label>5.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Rhee</surname>
            <given-names>CM</given-names>
          </name>
          <name>
            <surname>Kovesdy</surname>
            <given-names>CP</given-names>
          </name>
          <name>
            <surname>Ravel</surname>
            <given-names>VA</given-names>
          </name>
          <name>
            <surname>Streja</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Brunelli</surname>
            <given-names>SM</given-names>
          </name>
          <name>
            <surname>Soohoo</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Sumida</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Molnar</surname>
            <given-names>MZ</given-names>
          </name>
          <name>
            <surname>Brent</surname>
            <given-names>GA</given-names>
          </name>
          <name>
            <surname>Nguyen</surname>
            <given-names>DV</given-names>
          </name>
          <name>
            <surname>Kalantar-Zadeh</surname>
            <given-names>K</given-names>
          </name>
        </person-group>
        <article-title>Association of glycemic status during progression of chronic kidney disease with early dialysis mortality in patients with diabetes</article-title>
        <source>Diabetes Care</source>
        <year>2017</year>
        <volume>40</volume>
        <fpage>1050</fpage>
        <lpage>1057</lpage>
        <pub-id pub-id-type="doi">10.2337/dc17-0110</pub-id>
        <pub-id pub-id-type="pmid">28592525</pub-id>
      </element-citation>
    </ref>
    <ref id="CR6">
      <label>6.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ligtenberg</surname>
            <given-names>G</given-names>
          </name>
        </person-group>
        <article-title>Regulation of blood pressure in chronic renal failure: determinants of hypertension and dialysis-related hypotension</article-title>
        <source>Neth J Med</source>
        <year>1999</year>
        <volume>55</volume>
        <fpage>13</fpage>
        <lpage>18</lpage>
        <pub-id pub-id-type="doi">10.1016/S0300-2977(99)00024-8</pub-id>
        <pub-id pub-id-type="pmid">10431550</pub-id>
      </element-citation>
    </ref>
    <ref id="CR7">
      <label>7.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Pyram</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Kansara</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Banerji</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Loney-Hutchinson</surname>
            <given-names>L</given-names>
          </name>
        </person-group>
        <article-title>Chronic kidney disease and diabetes</article-title>
        <source>Maturitas</source>
        <year>2012</year>
        <volume>71</volume>
        <fpage>94</fpage>
        <lpage>103</lpage>
        <pub-id pub-id-type="doi">10.1016/j.maturitas.2011.11.009</pub-id>
        <pub-id pub-id-type="pmid">22137331</pub-id>
      </element-citation>
    </ref>
    <ref id="CR8">
      <label>8.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Genovese</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Manresa</surname>
            <given-names>AA</given-names>
          </name>
          <name>
            <surname>Leeming</surname>
            <given-names>DJ</given-names>
          </name>
          <name>
            <surname>Karsdal</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Boor</surname>
            <given-names>P</given-names>
          </name>
        </person-group>
        <article-title>The extracellular matrix in the kidney: a source of novel non-invasive biomarkers of kidney fibrosis?</article-title>
        <source>Fibrogenesis Tissue Repair</source>
        <year>2014</year>
        <volume>7</volume>
        <fpage>4</fpage>
        <pub-id pub-id-type="doi">10.1186/1755-1536-7-4</pub-id>
        <pub-id pub-id-type="pmid">24678881</pub-id>
      </element-citation>
    </ref>
    <ref id="CR9">
      <label>9.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bakris</surname>
            <given-names>GL</given-names>
          </name>
          <name>
            <surname>Sarafidis</surname>
            <given-names>PA</given-names>
          </name>
          <name>
            <surname>Weir</surname>
            <given-names>MR</given-names>
          </name>
          <name>
            <surname>Dahlöf</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Pitt</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Jamerson</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Velazquez</surname>
            <given-names>EJ</given-names>
          </name>
          <name>
            <surname>Staikos-Byrne</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Kelly</surname>
            <given-names>RY</given-names>
          </name>
          <name>
            <surname>Shi</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Chiang</surname>
            <given-names>YT</given-names>
          </name>
          <name>
            <surname>Weber</surname>
            <given-names>MA</given-names>
          </name>
        </person-group>
        <article-title>Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial</article-title>
        <source>Lancet</source>
        <year>2010</year>
        <volume>375</volume>
        <fpage>1173</fpage>
        <lpage>1181</lpage>
        <pub-id pub-id-type="doi">10.1016/S0140-6736(09)62100-0</pub-id>
        <pub-id pub-id-type="pmid">20170948</pub-id>
      </element-citation>
    </ref>
    <ref id="CR10">
      <label>10.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Marks</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Fluck</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Prescott</surname>
            <given-names>GJ</given-names>
          </name>
          <name>
            <surname>Robertson</surname>
            <given-names>LM</given-names>
          </name>
          <name>
            <surname>Simpson</surname>
            <given-names>WG</given-names>
          </name>
          <name>
            <surname>Smith</surname>
            <given-names>WC</given-names>
          </name>
          <name>
            <surname>Black</surname>
            <given-names>C</given-names>
          </name>
        </person-group>
        <article-title>Definitions of progression in chronic kidney disease–predictors and relationship to renal replacement therapy in a population cohort with a 6 year follow-up</article-title>
        <source>Nephrol Dial Transplant</source>
        <year>2014</year>
        <volume>29</volume>
        <fpage>333</fpage>
        <lpage>341</lpage>
        <pub-id pub-id-type="doi">10.1093/ndt/gft393</pub-id>
        <pub-id pub-id-type="pmid">24081862</pub-id>
      </element-citation>
    </ref>
    <ref id="CR11">
      <label>11.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Floege</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Barbour</surname>
            <given-names>SJ</given-names>
          </name>
          <name>
            <surname>Cattran</surname>
            <given-names>DC</given-names>
          </name>
          <name>
            <surname>Hogan</surname>
            <given-names>JJ</given-names>
          </name>
          <name>
            <surname>Nachman</surname>
            <given-names>PH</given-names>
          </name>
          <name>
            <surname>Tang</surname>
            <given-names>SCW</given-names>
          </name>
          <name>
            <surname>Wetzels</surname>
            <given-names>JFM</given-names>
          </name>
          <name>
            <surname>Cheung</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Wheeler</surname>
            <given-names>DC</given-names>
          </name>
          <name>
            <surname>Winkelmayer</surname>
            <given-names>WC</given-names>
          </name>
          <name>
            <surname>Rovin</surname>
            <given-names>BH</given-names>
          </name>
        </person-group>
        <article-title>Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference</article-title>
        <source>Kidney Int</source>
        <year>2019</year>
        <volume>95</volume>
        <fpage>268</fpage>
        <lpage>280</lpage>
        <pub-id pub-id-type="doi">10.1016/j.kint.2018.10.018</pub-id>
        <pub-id pub-id-type="pmid">30665568</pub-id>
      </element-citation>
    </ref>
    <ref id="CR12">
      <label>12.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Echouffo-Tcheugui</surname>
            <given-names>JB</given-names>
          </name>
          <name>
            <surname>Kengne</surname>
            <given-names>AP</given-names>
          </name>
        </person-group>
        <article-title>Risk models to predict chronic kidney disease and its progression: a systematic review</article-title>
        <source>PLoS Med</source>
        <year>2012</year>
        <volume>9</volume>
        <fpage>e1001344</fpage>
        <pub-id pub-id-type="doi">10.1371/journal.pmed.1001344</pub-id>
        <pub-id pub-id-type="pmid">23185136</pub-id>
      </element-citation>
    </ref>
    <ref id="CR13">
      <label>13.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tangri</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Stevens</surname>
            <given-names>LA</given-names>
          </name>
          <name>
            <surname>Griffith</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Tighiouart</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Djurdjev</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Naimark</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Levin</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Levey</surname>
            <given-names>AS</given-names>
          </name>
        </person-group>
        <article-title>A predictive model for progression of chronic kidney disease to kidney failure</article-title>
        <source>JAMA</source>
        <year>2011</year>
        <volume>305</volume>
        <fpage>1553</fpage>
        <lpage>1559</lpage>
        <pub-id pub-id-type="doi">10.1001/jama.2011.451</pub-id>
        <pub-id pub-id-type="pmid">21482743</pub-id>
      </element-citation>
    </ref>
    <ref id="CR14">
      <label>14.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Desai</surname>
            <given-names>AS</given-names>
          </name>
          <name>
            <surname>Toto</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Jarolim</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Uno</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Eckardt</surname>
            <given-names>KU</given-names>
          </name>
          <name>
            <surname>Kewalramani</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Levey</surname>
            <given-names>AS</given-names>
          </name>
          <name>
            <surname>Lewis</surname>
            <given-names>EF</given-names>
          </name>
          <name>
            <surname>McMurray</surname>
            <given-names>JJ</given-names>
          </name>
          <name>
            <surname>Parving</surname>
            <given-names>HH</given-names>
          </name>
          <name>
            <surname>Solomon</surname>
            <given-names>SD</given-names>
          </name>
          <name>
            <surname>Pfeffer</surname>
            <given-names>MA</given-names>
          </name>
        </person-group>
        <article-title>Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD</article-title>
        <source>Am J Kidney Dis</source>
        <year>2011</year>
        <volume>58</volume>
        <fpage>717</fpage>
        <lpage>728</lpage>
        <pub-id pub-id-type="doi">10.1053/j.ajkd.2011.05.020</pub-id>
        <pub-id pub-id-type="pmid">21820220</pub-id>
      </element-citation>
    </ref>
    <ref id="CR15">
      <label>15.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hallan</surname>
            <given-names>SI</given-names>
          </name>
          <name>
            <surname>Ritz</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Lydersen</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Romundstad</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Kvenild</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Orth</surname>
            <given-names>SR</given-names>
          </name>
        </person-group>
        <article-title>Combining GFR and albuminuria to classify CKD improves prediction of ESRD</article-title>
        <source>J Am Soc Nephrol</source>
        <year>2009</year>
        <volume>20</volume>
        <fpage>1069</fpage>
        <lpage>1077</lpage>
        <pub-id pub-id-type="doi">10.1681/ASN.2008070730</pub-id>
        <pub-id pub-id-type="pmid">19357254</pub-id>
      </element-citation>
    </ref>
    <ref id="CR16">
      <label>16.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kent</surname>
            <given-names>DM</given-names>
          </name>
          <name>
            <surname>Jafar</surname>
            <given-names>TH</given-names>
          </name>
          <name>
            <surname>Hayward</surname>
            <given-names>RA</given-names>
          </name>
          <name>
            <surname>Tighiouart</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Landa</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>de Jong</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>de Zeeuw</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Remuzzi</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Kamper</surname>
            <given-names>AL</given-names>
          </name>
          <name>
            <surname>Levey</surname>
            <given-names>AS</given-names>
          </name>
        </person-group>
        <article-title>Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease</article-title>
        <source>J Am Soc Nephrol</source>
        <year>2007</year>
        <volume>18</volume>
        <fpage>1959</fpage>
        <lpage>1965</lpage>
        <pub-id pub-id-type="doi">10.1681/ASN.2006101081</pub-id>
        <pub-id pub-id-type="pmid">17475813</pub-id>
      </element-citation>
    </ref>
    <ref id="CR17">
      <label>17.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Iimori</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Naito</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Noda</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Sato</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Nomura</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Sohara</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Okado</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Sasaki</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Uchida</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Rai</surname>
            <given-names>T</given-names>
          </name>
        </person-group>
        <article-title>Prognosis of chronic kidney disease with normal-range proteinuria: The CKD-ROUTE study</article-title>
        <source>PLoS One</source>
        <year>2018</year>
        <volume>13</volume>
        <fpage>e0190493</fpage>
        <pub-id pub-id-type="doi">10.1371/journal.pone.0190493</pub-id>
        <pub-id pub-id-type="pmid">29342207</pub-id>
      </element-citation>
    </ref>
    <ref id="CR18">
      <label>18.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Cheung</surname>
            <given-names>AK</given-names>
          </name>
          <name>
            <surname>Chang</surname>
            <given-names>TI</given-names>
          </name>
          <name>
            <surname>Cushman</surname>
            <given-names>WC</given-names>
          </name>
          <name>
            <surname>Furth</surname>
            <given-names>SL</given-names>
          </name>
          <name>
            <surname>Hou</surname>
            <given-names>FF</given-names>
          </name>
          <name>
            <surname>Ix</surname>
            <given-names>JH</given-names>
          </name>
          <name>
            <surname>Knoll</surname>
            <given-names>GA</given-names>
          </name>
          <name>
            <surname>Muntner</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Pecoits-Filho</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Sarnak</surname>
            <given-names>MJ</given-names>
          </name>
          <name>
            <surname>Tobe</surname>
            <given-names>SW</given-names>
          </name>
          <name>
            <surname>Tomson</surname>
            <given-names>CRV</given-names>
          </name>
          <name>
            <surname>Lytvyn</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Craig</surname>
            <given-names>JC</given-names>
          </name>
          <name>
            <surname>Tunnicliffe</surname>
            <given-names>DJ</given-names>
          </name>
          <name>
            <surname>Howell</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Tonelli</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Cheung</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Earley</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Mann</surname>
            <given-names>JFE</given-names>
          </name>
        </person-group>
        <article-title>Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease</article-title>
        <source>Kidney Int</source>
        <year>2021</year>
        <volume>99</volume>
        <fpage>559</fpage>
        <lpage>569</lpage>
        <pub-id pub-id-type="doi">10.1016/j.kint.2020.10.026</pub-id>
        <pub-id pub-id-type="pmid">33637203</pub-id>
      </element-citation>
    </ref>
    <ref id="CR19">
      <label>19.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tang</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Jiang</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Qing</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Zeng</surname>
            <given-names>Z</given-names>
          </name>
        </person-group>
        <article-title>Systematic construction and validation of an epithelial-mesenchymal transition risk model to predict prognosis of lung adenocarcinoma</article-title>
        <source>Aging (Albany NY)</source>
        <year>2020</year>
        <volume>13</volume>
        <fpage>794</fpage>
        <lpage>812</lpage>
        <pub-id pub-id-type="doi">10.18632/aging.202186</pub-id>
        <pub-id pub-id-type="pmid">33340396</pub-id>
      </element-citation>
    </ref>
    <ref id="CR20">
      <label>20.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tang</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Hu</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Zeng</surname>
            <given-names>Z</given-names>
          </name>
        </person-group>
        <article-title>A novel risk score based on a combined signature of 10 immune system genes to predict bladder cancer prognosis</article-title>
        <source>Int Immunopharmacol</source>
        <year>2020</year>
        <volume>87</volume>
        <fpage>106851</fpage>
        <pub-id pub-id-type="doi">10.1016/j.intimp.2020.106851</pub-id>
        <pub-id pub-id-type="pmid">32763782</pub-id>
      </element-citation>
    </ref>
    <ref id="CR21">
      <label>21.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>He</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Tang</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Zeng</surname>
            <given-names>Z</given-names>
          </name>
        </person-group>
        <article-title>Development and validation of a nomogram with an epigenetic signature for predicting survival in patients with lung adenocarcinoma</article-title>
        <source>Aging</source>
        <year>2020</year>
        <volume>12</volume>
        <fpage>23200</fpage>
        <lpage>23216</lpage>
        <?supplied-pmid 33221751?>
        <pub-id pub-id-type="pmid">33221751</pub-id>
      </element-citation>
    </ref>
    <ref id="CR22">
      <label>22.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tang</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Ye</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Yan</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Feng</surname>
            <given-names>Z</given-names>
          </name>
        </person-group>
        <article-title>A simple-to-use web-based calculator for survival prediction in Parkinson's disease</article-title>
        <source>Aging</source>
        <year>2021</year>
        <volume>13</volume>
        <fpage>5238</fpage>
        <lpage>5249</lpage>
        <pub-id pub-id-type="doi">10.18632/aging.202443</pub-id>
        <pub-id pub-id-type="pmid">33535176</pub-id>
      </element-citation>
    </ref>
    <ref id="CR23">
      <label>23.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ramanathan</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Padmanabhan</surname>
            <given-names>G</given-names>
          </name>
        </person-group>
        <article-title>Soluble neprilysin: A versatile biomarker for heart failure, cardiovascular diseases and diabetic complications-A systematic review</article-title>
        <source>Indian Heart J</source>
        <year>2020</year>
        <volume>72</volume>
        <fpage>14</fpage>
        <lpage>19</lpage>
        <pub-id pub-id-type="doi">10.1016/j.ihj.2020.01.006</pub-id>
        <pub-id pub-id-type="pmid">32423555</pub-id>
      </element-citation>
    </ref>
    <ref id="CR24">
      <label>24.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tang</surname>
            <given-names>YL</given-names>
          </name>
          <name>
            <surname>Dong</surname>
            <given-names>XY</given-names>
          </name>
          <name>
            <surname>Zeng</surname>
            <given-names>ZG</given-names>
          </name>
          <name>
            <surname>Feng</surname>
            <given-names>Z</given-names>
          </name>
        </person-group>
        <article-title>Gene expression-based analysis identified NTNG1 and HGF as biomarkers for diabetic kidney disease</article-title>
        <source>Medicine (Baltimore)</source>
        <year>2020</year>
        <volume>99</volume>
        <fpage>e18596</fpage>
        <pub-id pub-id-type="doi">10.1097/MD.0000000000018596</pub-id>
        <pub-id pub-id-type="pmid">31895808</pub-id>
      </element-citation>
    </ref>
    <ref id="CR25">
      <label>25.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Barrett</surname>
            <given-names>EJ</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Khamaisi</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>King</surname>
            <given-names>GL</given-names>
          </name>
          <name>
            <surname>Klein</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Klein</surname>
            <given-names>BEK</given-names>
          </name>
          <name>
            <surname>Hughes</surname>
            <given-names>TM</given-names>
          </name>
          <name>
            <surname>Craft</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Freedman</surname>
            <given-names>BI</given-names>
          </name>
          <name>
            <surname>Bowden</surname>
            <given-names>DW</given-names>
          </name>
          <name>
            <surname>Vinik</surname>
            <given-names>AI</given-names>
          </name>
          <name>
            <surname>Casellini</surname>
            <given-names>CM</given-names>
          </name>
        </person-group>
        <article-title>Diabetic microvascular disease: an Endocrine Society Scientific Statement</article-title>
        <source>J Clin Endocrinol Metab</source>
        <year>2017</year>
        <volume>102</volume>
        <fpage>4343</fpage>
        <lpage>4410</lpage>
        <pub-id pub-id-type="doi">10.1210/jc.2017-01922</pub-id>
        <pub-id pub-id-type="pmid">29126250</pub-id>
      </element-citation>
    </ref>
    <ref id="CR26">
      <label>26.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Li</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Hu</surname>
            <given-names>Q</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Liang</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Xiang</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Hsiao</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Nguyen</surname>
            <given-names>TK</given-names>
          </name>
          <name>
            <surname>Park</surname>
            <given-names>PK</given-names>
          </name>
          <name>
            <surname>Egranov</surname>
            <given-names>SD</given-names>
          </name>
          <name>
            <surname>Ambati</surname>
            <given-names>CR</given-names>
          </name>
          <name>
            <surname>Putluri</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Hawke</surname>
            <given-names>DH</given-names>
          </name>
          <name>
            <surname>Han</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Hung</surname>
            <given-names>MC</given-names>
          </name>
          <name>
            <surname>Danesh</surname>
            <given-names>FR</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Lin</surname>
            <given-names>C</given-names>
          </name>
        </person-group>
        <article-title>PTEN-induced partial epithelial-mesenchymal transition drives diabetic kidney disease</article-title>
        <source>J Clin Invest</source>
        <year>2019</year>
        <volume>129</volume>
        <fpage>1129</fpage>
        <lpage>1151</lpage>
        <pub-id pub-id-type="doi">10.1172/JCI121987</pub-id>
        <pub-id pub-id-type="pmid">30741721</pub-id>
      </element-citation>
    </ref>
    <ref id="CR27">
      <label>27.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Fernandez-Fernandez</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Ortiz</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Gomez-Guerrero</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Egido</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>Therapeutic approaches to diabetic nephropathy–beyond the RAS</article-title>
        <source>Nat Rev Nephrol</source>
        <year>2014</year>
        <volume>10</volume>
        <fpage>325</fpage>
        <lpage>346</lpage>
        <pub-id pub-id-type="doi">10.1038/nrneph.2014.74</pub-id>
        <pub-id pub-id-type="pmid">24802062</pub-id>
      </element-citation>
    </ref>
    <ref id="CR28">
      <label>28.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Liao</surname>
            <given-names>LN</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>CS</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>CI</given-names>
          </name>
          <name>
            <surname>Lin</surname>
            <given-names>WY</given-names>
          </name>
          <name>
            <surname>Lin</surname>
            <given-names>CH</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>TC</given-names>
          </name>
          <name>
            <surname>Lin</surname>
            <given-names>CC</given-names>
          </name>
        </person-group>
        <article-title>Three-year incidence of elevated albuminuria and associated factors in a population-based cohort: The Taichung Community Health Study</article-title>
        <source>Eur J Prev Cardiol</source>
        <year>2015</year>
        <volume>22</volume>
        <fpage>788</fpage>
        <lpage>797</lpage>
        <pub-id pub-id-type="doi">10.1177/2047487314537918</pub-id>
        <pub-id pub-id-type="pmid">24902714</pub-id>
      </element-citation>
    </ref>
    <ref id="CR29">
      <label>29.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kramer</surname>
            <given-names>HJ</given-names>
          </name>
          <name>
            <surname>Nguyen</surname>
            <given-names>QD</given-names>
          </name>
          <name>
            <surname>Curhan</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Hsu</surname>
            <given-names>CY</given-names>
          </name>
        </person-group>
        <article-title>Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus</article-title>
        <source>JAMA</source>
        <year>2003</year>
        <volume>289</volume>
        <fpage>3273</fpage>
        <lpage>3277</lpage>
        <pub-id pub-id-type="doi">10.1001/jama.289.24.3273</pub-id>
        <pub-id pub-id-type="pmid">12824208</pub-id>
      </element-citation>
    </ref>
    <ref id="CR30">
      <label>30.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Retnakaran</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Cull</surname>
            <given-names>CA</given-names>
          </name>
          <name>
            <surname>Thorne</surname>
            <given-names>KI</given-names>
          </name>
          <name>
            <surname>Adler</surname>
            <given-names>AI</given-names>
          </name>
          <name>
            <surname>Holman</surname>
            <given-names>RR</given-names>
          </name>
        </person-group>
        <article-title>Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74</article-title>
        <source>Diabetes</source>
        <year>2006</year>
        <volume>55</volume>
        <fpage>1832</fpage>
        <lpage>1839</lpage>
        <pub-id pub-id-type="doi">10.2337/db05-1620</pub-id>
        <pub-id pub-id-type="pmid">16731850</pub-id>
      </element-citation>
    </ref>
    <ref id="CR31">
      <label>31.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Garg</surname>
            <given-names>AX</given-names>
          </name>
          <name>
            <surname>Kiberd</surname>
            <given-names>BA</given-names>
          </name>
          <name>
            <surname>Clark</surname>
            <given-names>WF</given-names>
          </name>
          <name>
            <surname>Haynes</surname>
            <given-names>RB</given-names>
          </name>
          <name>
            <surname>Clase</surname>
            <given-names>CM</given-names>
          </name>
        </person-group>
        <article-title>Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III</article-title>
        <source>Kidney Int</source>
        <year>2002</year>
        <volume>61</volume>
        <fpage>2165</fpage>
        <lpage>2175</lpage>
        <pub-id pub-id-type="doi">10.1046/j.1523-1755.2002.00356.x</pub-id>
        <pub-id pub-id-type="pmid">12028457</pub-id>
      </element-citation>
    </ref>
    <ref id="CR32">
      <label>32.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Haller</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Ito</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Izzo</surname>
            <given-names>JL</given-names>
            <suffix>Jr</suffix>
          </name>
          <name>
            <surname>Januszewicz</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Katayama</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Menne</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Mimran</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Rabelink</surname>
            <given-names>TJ</given-names>
          </name>
          <name>
            <surname>Ritz</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Ruilope</surname>
            <given-names>LM</given-names>
          </name>
          <name>
            <surname>Rump</surname>
            <given-names>LC</given-names>
          </name>
          <name>
            <surname>Viberti</surname>
            <given-names>G</given-names>
          </name>
        </person-group>
        <article-title>Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes</article-title>
        <source>N Engl J Med</source>
        <year>2011</year>
        <volume>364</volume>
        <fpage>907</fpage>
        <lpage>917</lpage>
        <pub-id pub-id-type="doi">10.1056/NEJMoa1007994</pub-id>
        <pub-id pub-id-type="pmid">21388309</pub-id>
      </element-citation>
    </ref>
    <ref id="CR33">
      <label>33.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Mann</surname>
            <given-names>JF</given-names>
          </name>
          <name>
            <surname>Schmieder</surname>
            <given-names>RE</given-names>
          </name>
          <name>
            <surname>McQueen</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Dyal</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Schumacher</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Pogue</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Maggioni</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Budaj</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Chaithiraphan</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Dickstein</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Keltai</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Metsärinne</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Oto</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Parkhomenko</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Piegas</surname>
            <given-names>LS</given-names>
          </name>
          <name>
            <surname>Svendsen</surname>
            <given-names>TL</given-names>
          </name>
          <name>
            <surname>Teo</surname>
            <given-names>KK</given-names>
          </name>
          <name>
            <surname>Yusuf</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <article-title>Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial</article-title>
        <source>Lancet</source>
        <year>2008</year>
        <volume>372</volume>
        <fpage>547</fpage>
        <lpage>553</lpage>
        <pub-id pub-id-type="doi">10.1016/S0140-6736(08)61236-2</pub-id>
        <pub-id pub-id-type="pmid">18707986</pub-id>
      </element-citation>
    </ref>
    <ref id="CR34">
      <label>34.</label>
      <mixed-citation publication-type="other">George C, Matsha TE, Erasmus RT and Kengne AP. Haematological profile of chronic kidney disease in a mixed-ancestry South African population: a cross-sectional study. BMJ Open 2018; 8: e025694.</mixed-citation>
    </ref>
    <ref id="CR35">
      <label>35.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Choi</surname>
            <given-names>HY</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>TY</given-names>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>SH</given-names>
          </name>
          <name>
            <surname>Jhee</surname>
            <given-names>JH</given-names>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>YK</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>HJ</given-names>
          </name>
          <name>
            <surname>Park</surname>
            <given-names>HC</given-names>
          </name>
        </person-group>
        <article-title>Kidney mesenchymal stem cell-derived extracellular vesicles engineered to express erythropoietin improve renal anemia in mice with chronic kidney disease</article-title>
        <source>Stem Cell Rev Rep</source>
        <year>2021</year>
        <pub-id pub-id-type="doi">10.1007/s12015-021-10141-x</pub-id>
        <?supplied-pmid 33651336?>
        <pub-id pub-id-type="pmid">33651336</pub-id>
      </element-citation>
    </ref>
    <ref id="CR36">
      <label>36.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Valderrábano</surname>
            <given-names>F</given-names>
          </name>
        </person-group>
        <article-title>Erythropoietin in chronic renal failure</article-title>
        <source>Kidney Int</source>
        <year>1996</year>
        <volume>50</volume>
        <fpage>1373</fpage>
        <lpage>1391</lpage>
        <pub-id pub-id-type="doi">10.1038/ki.1996.452</pub-id>
        <pub-id pub-id-type="pmid">8887302</pub-id>
      </element-citation>
    </ref>
    <ref id="CR37">
      <label>37.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Benz</surname>
            <given-names>RL</given-names>
          </name>
          <name>
            <surname>Pressman</surname>
            <given-names>MR</given-names>
          </name>
          <name>
            <surname>Hovick</surname>
            <given-names>ET</given-names>
          </name>
          <name>
            <surname>Peterson</surname>
            <given-names>DD</given-names>
          </name>
        </person-group>
        <article-title>A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients (The SLEEPO study)</article-title>
        <source>Am J Kidney Dis</source>
        <year>1999</year>
        <volume>34</volume>
        <fpage>1089</fpage>
        <lpage>1095</lpage>
        <pub-id pub-id-type="doi">10.1016/S0272-6386(99)70015-6</pub-id>
        <pub-id pub-id-type="pmid">10585319</pub-id>
      </element-citation>
    </ref>
    <ref id="CR38">
      <label>38.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Levin</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Stevens</surname>
            <given-names>PE</given-names>
          </name>
        </person-group>
        <article-title>Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward</article-title>
        <source>Kidney Int</source>
        <year>2014</year>
        <volume>85</volume>
        <fpage>49</fpage>
        <lpage>61</lpage>
        <pub-id pub-id-type="doi">10.1038/ki.2013.444</pub-id>
        <pub-id pub-id-type="pmid">24284513</pub-id>
      </element-citation>
    </ref>
    <ref id="CR39">
      <label>39.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wakai</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Kawamura</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Endoh</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Kojima</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Tomino</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Tamakoshi</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Ohno</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Inaba</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Sakai</surname>
            <given-names>H</given-names>
          </name>
        </person-group>
        <article-title>A scoring system to predict renal outcome in IgA nephropathy: from a nationwide prospective study</article-title>
        <source>Nephrol Dial Trans</source>
        <year>2006</year>
        <volume>21</volume>
        <fpage>2800</fpage>
        <lpage>2808</lpage>
        <pub-id pub-id-type="doi">10.1093/ndt/gfl342</pub-id>
      </element-citation>
    </ref>
    <ref id="CR40">
      <label>40.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Johnson</surname>
            <given-names>ES</given-names>
          </name>
          <name>
            <surname>Thorp</surname>
            <given-names>ML</given-names>
          </name>
          <name>
            <surname>Platt</surname>
            <given-names>RW</given-names>
          </name>
          <name>
            <surname>Smith</surname>
            <given-names>DH</given-names>
          </name>
        </person-group>
        <article-title>Predicting the risk of dialysis and transplant among patients with CKD: a retrospective cohort study</article-title>
        <source>Am J Kidney Dis</source>
        <year>2008</year>
        <volume>52</volume>
        <fpage>653</fpage>
        <lpage>660</lpage>
        <pub-id pub-id-type="doi">10.1053/j.ajkd.2008.04.026</pub-id>
        <pub-id pub-id-type="pmid">18585833</pub-id>
      </element-citation>
    </ref>
  </ref-list>
</back>
